David James VanderWeele

1.9k total citations
57 papers, 1.0k citations indexed

About

David James VanderWeele is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, David James VanderWeele has authored 57 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pulmonary and Respiratory Medicine, 26 papers in Oncology and 17 papers in Molecular Biology. Recurrent topics in David James VanderWeele's work include Prostate Cancer Treatment and Research (37 papers), Radiopharmaceutical Chemistry and Applications (10 papers) and PARP inhibition in cancer therapy (10 papers). David James VanderWeele is often cited by papers focused on Prostate Cancer Treatment and Research (37 papers), Radiopharmaceutical Chemistry and Applications (10 papers) and PARP inhibition in cancer therapy (10 papers). David James VanderWeele collaborates with scholars based in United States, United Kingdom and Canada. David James VanderWeele's co-authors include Charles M. Rudin, Rixin Zhou, Zejia Yang, Kenneth Newkirk, Eleanor G. Zuhowski, Merrill J. Egorin, Kevin J. Cullen, Lisa M. Schumaker, William E. Evans and Monique L. den Boer and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

David James VanderWeele

50 papers receiving 998 citations

Peers

David James VanderWeele

PRM

ONCOL

IMMUN

Zhonghua Tao China

Zhengtang Chen China

Justine Y. Bruce United States

Holger H.H. Erb Germany

Yuxi Zhu China

Hefen Sun China

Gregory Dyson United States

Michaela J. Higgins United States

Daniel C. Christoph Germany

Hae Hyun Jung South Korea

Zhonghua Tao China

David James VanderWeele

582 ×1.2

219 ×0.6

PRM

419 ×1.4

ONCOL

374 ×1.4

98 ×0.9

IMMUN

Citations per year, relative to David James VanderWeele David James VanderWeele (= 1×) peers Zhonghua Tao

Countries citing papers authored by David James VanderWeele

Since Specialization

Citations

This map shows the geographic impact of David James VanderWeele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David James VanderWeele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David James VanderWeele more than expected).

Fields of papers citing papers by David James VanderWeele

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David James VanderWeele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David James VanderWeele. The network helps show where David James VanderWeele may publish in the future.

Co-authorship network of co-authors of David James VanderWeele

This figure shows the co-authorship network connecting the top 25 collaborators of David James VanderWeele. A scholar is included among the top collaborators of David James VanderWeele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David James VanderWeele. David James VanderWeele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aggarwal, Rahul, Jacqueline Vuky, David James VanderWeele, et al.. (2025). Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 43(15). 1824–1834. 5 indexed citations

Li, Yutai, et al.. (2025). Response to pembrolizumab in advanced prostate cancer with predictive biomarkers. The Oncologist. 30(3). 1 indexed citations

Morgans, Alicia K., James C. Jackson, Charles J. Ryan, et al.. (2025). Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP): A comparison of enzalutamide vs abiraterone acetate.. Journal of Clinical Oncology. 43(5_suppl). 131–131.

Li, Eric V., J. Proudfoot, Adam B. Weiner, et al.. (2025). Prevalence of Potential Candidates for Targeted Therapies According to Treatment-related Transcriptomic Signatures Among 140 548 Patients with Nonmetastatic Prostate Cancer. European Urology Oncology. 8(4). 1050–1058. 1 indexed citations

Wang, John S., et al.. (2025). Durable response to treatment of an atypical desmoplastic small round cell tumor with enfortumab-vedotin. Journal of Cancer Research and Clinical Oncology. 151(2). 73–73.

Hussain, Maha, Masha Kocherginsky, Parminder Singh, et al.. (2024). A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).. Journal of Clinical Oncology. 42(16_suppl). 4574–4574. 2 indexed citations

Stewart, Tyler F., Sarah E. Fenton, Shayan Nazari, et al.. (2024). Landscape analysis and oncologic outcomes in advanced urothelial carcinoma (UC) by NECTIN4 RNA expression.. Journal of Clinical Oncology. 42(16_suppl). 4585–4585. 1 indexed citations

Fenton, Sarah E., Masha Kocherginsky, David James VanderWeele, & Maha Hussain. (2024). A randomized phase II study of ADT + abiraterone versus ADT + abiraterone + docetaxel in patients with low-volume metastatic hormone-sensitive prostate cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS5121–TPS5121.

Fenton, Sarah E. & David James VanderWeele. (2023). Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma. Frontiers in Oncology. 12. 1069356–1069356. 7 indexed citations

10.

Madan, Ravi A., Fatima Karzai, David James VanderWeele, Heather H. Cheng, & Johann S. de Bono. (2023). Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits. Journal of Clinical Oncology. 41(36). 5501–5504. 5 indexed citations

11.

Farrukh, Hizra, Zheng Zhu, Shaoming Zhu, et al.. (2023). A phase II trial with copanlisib plus avelumab as maintenance therapy for metastatic bladder cancer after platinum-based chemotherapy.. Journal of Clinical Oncology. 41(16_suppl). TPS4610–TPS4610. 2 indexed citations

12.

Baker, Abu, Jochen H. Lorch, David James VanderWeele, & Bin Zhang. (2023). Smart Nanocarriers for the Targeted Delivery of Therapeutic Nucleic Acid for Cancer Immunotherapy. Pharmaceutics. 15(6). 1743–1743. 13 indexed citations

13.

VanderWeele, David James, Masha Kocherginsky, Vinay Sagar, et al.. (2022). A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 20(6). 575–580. 2 indexed citations

14.

Aggarwal, Rahul, Jacqueline Vuky, David James VanderWeele, et al.. (2021). 591P A first-in-human study of FOR46 in men with metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 32. S639–S639. 1 indexed citations

15.

Adelaiye‐Ogala, Remi, Berkley E. Gryder, Yen Thi Minh Nguyen, et al.. (2020). Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor. Molecular Cancer Therapeutics. 19(7). 1436–1447. 34 indexed citations

16.

Boettcher, Adeline N., Ahmed Usman, Amee Morgans, et al.. (2019). Past, Current, and Future of Immunotherapies for Prostate Cancer. Frontiers in Oncology. 9. 884–884. 85 indexed citations

17.

VanderWeele, David James, Barış Türkbey, Fatima Karzai, et al.. (2018). Neoadjuvant enzalutamide and androgen deprivation therapy for high-risk prostate cancer: Early results from a feasibility trial.. Journal of Clinical Oncology. 36(6_suppl). 94–94. 1 indexed citations

18.

Lack, Justin, Marc Gillard, Maggie Cam, Gladell P. Paner, & David James VanderWeele. (2017). Circulating tumor cells capture disease evolution in advanced prostate cancer. Journal of Translational Medicine. 15(1). 44–44. 26 indexed citations

19.

Packiam, Vignesh T., Sanjay G. Patel, Joseph J. Pariser, et al.. (2015). Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. Urology. 86(4). 777–782. 27 indexed citations

20.

VanderWeele, David James, Gladell P. Paner, Gini F. Fleming, & Russell Z. Szmulewitz. (2015). Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer – A Case Report. Frontiers in Oncology. 5. 169–169. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact